1 / 6

Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Assessment

Tumor Necrosis Factor Receptor Superfamily Member 5 Report explained that the expression of CD40 is diverse. CD40 is expressed on a wide range of tumor cells including hodgkin's and non-hodgkin's lymphomas, myeloma and some carcinomas including nasopharynx, bladder, kidney and ovary. As observed by the study, tumor necrosis factor promotes an inflammatory response to remove damaging stimuli which include damaged cells, irritants, or pathogens and then begins the therapeutic process. For more details click the below URL<br>http://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface-antigen-cd40-or-bp50-or-cdw40-or-cd40l-receptor-or-tnfrsf5-or-cd40-pipeline-review-h2-2016-report.html<br>

markresearch
Download Presentation

Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Assessment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tumor Necrosis Factor Receptor Superfamily Member 5 Pipeline Assessment and Global Drug Forecast in H2 2016 N N N No o o o o o o of f f f P P P Pa a a ag g g ge e e es s s s – – 7 70 0 P P P Pu u u ub b b bl l l li i i is s s sh h h hi i i in n n ng g g g D D D Da a a at t t te e e e - - O Oc ct to ob be er r, , 2 20 01 16 6 B B B Br r r ro o o ow w w ws s s se e e e d d d de e e et t t ta a a ai i i il l l le e e ed d d d T T T TO O O OC C C C, , , , T T T Ta a a ab b b bl l l le e e es s s s, , , , F F F Fi i i ig g g gu u u ur r r re e e es s s s, , , , a a a an n n nd d d d C C C Ch h h ha a a ar r r rt t t ts s s s i i i in n n n G G G Gl l l lo o o ob b b ba a a al l l l S S S Se e e er r r ri i i ia a a al l l l D D D De e e ev v v vi i i ic c c ce e e e S S S Se e e er r r rv v v ve e e er r r r C C C Co o o on n n ns s s su u u um m m mp p p pt t t ti i i io o o on n n n 2 2 2 20 0 0 01 1 1 16 6 6 6 M M M Ma a a ar r r rk k k ke e e et t t t R R R Re e e es s s se e e ea a a ar r r rc c c ch h h h R R R Re e e ep p p po o o or r r rt t t t a a a at t t t: : : : http://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface- antigen-cd40-or-bp50-or-cdw40-or-cd40l-receptor-or-tnfrsf5-or-cd40-pipeline-review-h2-2016-report.html Latest market pipeline analysis on the Tumor Necrosis Factor Receptor Superfamily has been released by Global Markets Direct. It has been added to the online database of Market Research Hub Hub (MRH). The report is built using data sourced from exclusive databases, SEC filings, clinical trial registries, conferences, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Market Research Tumor Necrosis Factor Receptor Superfamily Member 5 Report Tumor Necrosis Factor Receptor Superfamily Member 5 Report explained that the expression of CD40 is diverse. CD40 is expressed on a wide range of tumor cells including hodgkin's and non-hodgkin's lymphomas, myeloma and some carcinomas including nasopharynx, bladder, kidney and ovary. As observed by the study, tumor necrosis factor promotes an inflammatory response to remove damaging stimuli which include damaged cells, irritants, or pathogens and then begins the therapeutic process.

  2. T T T Ta a a ab b b bl l l le e e e o o o of f f f C C C Co o o on n n nt t t te e e en n n nt t t ts s s s Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) Overview 8 Therapeutics Development 9 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Stage of Development 9 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Therapy Area 10 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Indication 11 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Companies 15 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Universities/Institutes 18 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development 27 AbbVie Inc 27 Apexigen, Inc. 28 Apogenix GmbH 29 Boehringer Ingelheim GmbH 30 Bristol-Myers Squibb Company 31 Celldex Therapeutics, Inc. 32 F. Hoffmann-La Roche Ltd. 33 ImmuNext, Inc. 34 Johnson & Johnson 35 Request for Free Sample Report

  3. Kyowa Hakko Kirin Co., Ltd. 36 Novartis AG 37 Seattle Genetics, Inc. 38 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles 39 2C-10 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 ABBV-428 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 APG-1233 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 APX-005M - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 BI-655064 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 bleselumab - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 BMS-986090 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 CFZ-533 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 FFP-104 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 JNJ-64457107 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 KGYY-15 - Drug Profile 53 Request for Free Sample Report

  4. Product Description 53 Mechanism Of Action 53 R&D Progress 53 Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Monoclonal Antibodies to Agonize CD40 for Lymphoma - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 RG-7876 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 SEA-CD40 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Projects 60 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 62 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Featured News & Press Releases 63 Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 63 Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 63 Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohns Disease with anti-CD40 Monoclonal Antibody 64 Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 64 Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 65 Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M 66 Request for Free Sample Report

  5. May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform 66 Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial 67 Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial 67 Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors 68 Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70 R R R Re e e ep p p po o o or r r rt t t t D D D De e e et t t ta a a ai i i il l l ls s s s – – D D D Da a a at t t te e e e o o o of f f f P P P Pu u u ub b b bl l l li i i is s s sh h h hi i i in n n ng g g g – – O Oc ct to ob be er r, , 2 20 01 16 6 N N N No o o o o o o of f f f P P P Pa a a ag g g ge e e es s s s – – 7 70 0 S S S Si i i in n n ng g g gl l l le e e e U U U Us s s se e e er r r r L L L Li i i ic c c ce e e en n n ns s s se e e e – – $ $3 35 50 00 0 M M M Mu u u ul l l lt t t ti i i ip p p pl l l le e e e U U U Us s s se e e er r r r L L L Li i i ic c c ce e e en n n ns s s se e e e – – $ $7 70 00 00 0 A A A Ab b b bo o o ou u u ut t t t M M M Ma a a ar r r rk k k ke e e et t t t R R R Re e e es s s se e e ea a a ar r r rc c c ch h h h H H H HU U U UB B B B : : : : M Ma ar rk ke et t R Re es se ea ar rc ch h H HU UB B i is s t th he e c cr re ed di ib bl le e s so ou ur rc ce e f fo or r g ga ai in ni in ng g t th he e m ma ar rk ke et t r re es se ea ar rc ch h r re ep po or rt ts s t th ha at t w wi il ll l e ex xp po on ne en nt ti ia al ll ly y a ac cc ce el le er ra at te e y yo ou ur r b bu us si in ne es ss s. . W l le ea ad di in ng g r re ep po or rt t r re es se el ll le er rs s i in n t th he e b bu us si in ne es ss s w wo or rl ld d c co om mm mi it tt te ed d t to ow wa ar rd ds s o op pt ti im mi iz zi in ng g y yo ou ur r b bu us si in ne es ss s. . T Th he e r re ep po or rt ts s w we e p pr ro ov vi id de e a ar re e b ba as se ed d o on n a a r re es se ea ar rc ch h t th ha at t c co ov ve er rs s a a m ma ag gn ni it tu ud de e o of f f fa ac ct to or rs s s su uc ch h a as s t te ec ch hn no ol lo og gi ic ca al l e ev vo ol lu ut ti io on n, , e ec co on no om mi ic c s sh hi if ft ts s a an nd d a a d de et ta ai il le ed d s st tu ud dy y o of f m ma ar rk ke et t s se eg gm me en nt ts s. . Buy Report Now! We e a ar re e a am mo on ng g t th he e

  6. C C C Co o o on n n nt t t ta a a ac c c ct t t t– – – – 90 State Street, 90 State Street, Albany, NY 12207, Albany, NY 12207, United States United States Toll Free : 866 Toll Free : 866- -997 Tel : +1 Tel : +1- -518 518- -621 Email : Email : mailto:sales@marketresearchhub.com mailto:sales@marketresearchhub.com Website : Website : http://www.marketresearchhub.com/ http://www.marketresearchhub.com/ 997- -4948 (US 4948 (US- -Canada) 621- -2074 2074 Canada)

More Related